Seeking Alpha News (Fri, 1-Dec 5:29 PM ET)
Globe Newswire (Mon, 13-Nov 7:00 AM ET)
Globe Newswire (Fri, 10-Nov 8:57 AM ET)
Globe Newswire (Wed, 8-Nov 7:00 AM ET)
Globe Newswire (Tue, 17-Oct 4:05 PM ET)
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins
Globe Newswire (Tue, 10-Oct 7:00 AM ET)
Globe Newswire (Mon, 9-Oct 4:05 PM ET)
Globe Newswire (Wed, 4-Oct 8:00 AM ET)
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Akero Therapeutics trades on the NASDAQ stock market under the symbol AKRO.
As of December 6, 2023, AKRO stock price climbed to $19.06 with 1,059,796 million shares trading.
AKRO has a beta of 1.96, meaning it tends to be more sensitive to market movements. AKRO has a correlation of 0.04 to the broad based SPY ETF.
AKRO has a market cap of $1.06 billion. This is considered a Small Cap stock.
In the last 3 years, AKRO stock traded as high as $58.38 and as low as $7.52.
The top ETF exchange traded funds that AKRO belongs to (by Net Assets): XBI, IWM, VTI, VXF, IWO.
AKRO has underperformed the market in the last year with a return of -56.7%, while the SPY ETF gained +15.4%. In the last 3 month period, AKRO fell short of the market, returning -61.9%, while SPY returned +1.6%. However, in the most recent 2 weeks AKRO has outperformed the stock market by returning +18.6%, while SPY returned +0.3%.
AKRO support price is $17.47 and resistance is $19.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKRO stock will trade within this expected range on the day.